Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $4.44 in the prior trading day, Ventyx Biosciences Inc (NASDAQ: VTYX) closed at $4.48, up 0.90%. In other words, the price has increased by $0.90 from its previous closing price. On the day, 0.55 million shares were traded. VTYX stock price reached its highest trading level at $4.63 during the session, while it also had its lowest trading level at $4.38.
Ratios:
Our goal is to gain a better understanding of VTYX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.87 and its Current Ratio is at 11.87. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on March 12, 2024, Upgraded its rating to Overweight and sets its target price to $16 from $7 previously.
On March 12, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $12.
Wells Fargo Downgraded its Overweight to Equal Weight on November 07, 2023, whereas the target price for the stock was revised from $77 to $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 02 ’24 when Mohan Raju sold 4,312 shares for $5.40 per share. The transaction valued at 23,299 led to the insider holds 1,578,250 shares of the business.
Krueger Christopher W sold 1,651 shares of VTYX for $8,921 on Apr 02 ’24. The CHIEF BUSINESS OFFICER now owns 284,999 shares after completing the transaction at $5.40 per share. On Apr 02 ’24, another insider, Nuss John, who serves as the CHIEF SCIENTIFIC OFFICER of the company, sold 1,651 shares for $5.40 each. As a result, the insider received 8,921 and left with 264,998 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VTYX now has a Market Capitalization of 315836416 and an Enterprise Value of 25677226.
Stock Price History:
The Beta on a monthly basis for VTYX is 0.51, which has changed by -0.8818206 over the last 52 weeks, in comparison to a change of 0.25590587 over the same period for the S&P500. Over the past 52 weeks, VTYX has reached a high of $40.58, while it has fallen to a 52-week low of $1.87. The 50-Day Moving Average of the stock is -25.36%, while the 200-Day Moving Average is calculated to be -66.03%.
Shares Statistics:
The stock has traded on average 3.99M shares per day over the past 3-months and 1111330 shares per day over the last 10 days, according to various share statistics. A total of 59.24M shares are outstanding, with a floating share count of 56.85M. Insiders hold about 19.36% of the company’s shares, while institutions hold 74.10% stake in the company. Shares short for VTYX as of 1713139200 were 8376045 with a Short Ratio of 2.10, compared to 1710460800 on 9445442. Therefore, it implies a Short% of Shares Outstanding of 8376045 and a Short% of Float of 13.919999999999998.
Earnings Estimates
The performance of Ventyx Biosciences Inc (VTYX) in the stock market is under the watchful eye of 8.0 analysts actively contributing to its current rating.On average, analysts expect EPS of -$0.69 for the current quarter, with a high estimate of -$0.38 and a low estimate of -$0.86, while EPS last year was -$0.68. The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.34 and low estimates of -$0.86.
Analysts are recommending an EPS of between -$1.57 and -$4.18 for the fiscal current year, implying an average EPS of -$2.67. EPS for the following year is -$2.59, with 8.0 analysts recommending between -$1.25 and -$4.44.
